Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America QNRX
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea 348080
Radiopharm Theranostics Ltd Logo
Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.
United States of America RADX
Rallybio Corp Logo
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America RLYB
Rani Therapeutics Holdings, Inc. Logo
Develops a capsule to convert injectable biologics into oral pills for chronic diseases.
United States of America RANI
Rapport Therapeutics, Inc. Logo
Developing precision small molecule medicines for Central Nervous System (CNS) disorders.
United States of America RAPP
RAPT Therapeutics, Inc. Logo
Developing immune-targeting therapies for inflammatory and immunologic diseases.
United States of America RAPT

Talk to a Data Expert

Have a question? We'll get back to you promptly.